Company Filing History:
Years Active: 2003
Title: Paule Opolon: Innovator in Gene Therapy for Tumor Treatment
Introduction
Paule Opolon is a distinguished inventor based in Paris, France. He has made significant contributions to the field of gene therapy, particularly in the treatment of tumors. His innovative approach focuses on utilizing adenovirus vectors to deliver anti-angiogenic factors directly to tumor cells.
Latest Patents
Paule Opolon holds a patent for his invention titled "Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors." This groundbreaking invention relates to gene therapy aimed at treating tumors by introducing a gene encoding an anti-angiogenic factor into tumor cells. The use of a defective adenovirus vector has shown promise in inhibiting tumor growth and metastasis. Specifically, the delivery of a defective adenovirus expressing the amino terminal fragment of urokinase (ATF) has demonstrated remarkable effects in reducing neovascularization at the injection site. Additionally, the invention includes viral vectors that can be utilized in these therapeutic methods.
Career Highlights
Paule Opolon is associated with Gencell Sas, a company that focuses on innovative solutions in the field of gene therapy. His work has positioned him as a key figure in advancing therapeutic strategies for cancer treatment.
Collaborations
Paule has collaborated with notable colleagues, including Hong Li and He Lu, who have contributed to his research endeavors.
Conclusion
Paule Opolon is a pioneering inventor whose work in gene therapy has the potential to transform cancer treatment. His innovative patent highlights the importance of targeted therapies in combating tumors effectively.